Robert Wong, MD
Ophthalmology · Austin, TXNPI 1275699274
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $100,665 of the $113,427 with a category attached, or 88.7%. Baxter Healthcare accounts for 86.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $57,555 and has fallen 96.9% since, to $1,793 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $564.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$98K
- US Retina LLC$4K
- Novartis$3K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$1K
- AbbVie$832
- plus $5K from 24 others
Across 1,531 payments — averaging $4243.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.4M
- Bayer$1M
- Regeneron$975K
- Ocular Therapeutix, Inc.$722K
- Kyowa Kirin, Inc.$202K
- Boehringer Ingelheim International GmbH$113K
- plus $27K from 4 others
What the payments were for
- Consulting fees$100,66589%
- Grants$5000%
- Food & beverage$7,5057%
- Education$1060%
- Gifts$1760%
- Entertainment$1440%
- Ownership interest$1,5601%
- Other$2,7722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 24 | $97,590 |
| US Retina LLC | 7 | $4,331 |
| Novartis | 5 | $3,370 |
| Regeneron Healthcare Solutions, Inc. | 35 | $1,051 |
| Genentech USA, Inc. | 28 | $1,002 |
| AbbVie(2 entities) | 12 | $832 |
| Apellis Pharmaceuticals, Inc. | 19 | $782 |
| Alcon | 4 | $626 |
| Regeneron | 4 | $470 |
| Mallinckrodt Hospital Products Inc. | 14 | $400 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $381 |
| Astellas Pharma US Inc | 11 | $292 |
| Biotissue Holdings Inc. | 2 | $282 |
| Genentech, Inc. | 4 | $265 |
| Bausch & Lomb Americas Inc. | 5 | $195 |
| Eyepoint US, Inc. | 2 | $188 |
| Carl Zeiss Meditec, Inc. | 1 | $176 |
| Alimera Sciences, Inc. | 2 | $155 |
| Optos, Inc. | 1 | $144 |
| ANI Pharmaceuticals, Inc. | 5 | $135 |
| Astellas Pharma Global Development | 1 | $131 |
| Rxsight Inc | 1 | $127 |
| Amgen(2 entities) | 2 | $123 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Optovue, Inc. | 1 | $100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $60 |
| Ocular Therapeutix, Inc. | 2 | $55 |
| Dutch Ophthalmic, USA | 1 | $20 |
| Biogen | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hillrom - RetinaVue 700 Imager$97,590
- Hillrom - RetinaVue Network$97,590
- BEOVU$3,200
- OZURDEX$628
- Constellation$626
- VABYSMO$568
- EYLEA HD$408
- EYLEA$375
- PANORAMIC OPHTHALMOSCOPE$289
- OCT OPHTHALMOSCOPE$289
- CLARUS$176
- YUTIQ$169
- NFC-700$144
- Izervay$131
- RXSIGHT CONTACT LENS$127
- RXSIGHT INJECTOR CARTRIDGE$127
- RXSIGHT INJECTOR HANDPIECE$127
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$127
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$127
- Iluvien$127
How this compares
$113,427 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 19 | $3,370 |
| Prednisolone Acetate | 41 | $1,439 |
| Ketorolac Tromethamine | 27 | $936 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 72 | $835 |
| Timolol Maleate | 27 | $202 |
| Methylprednisolone | 16 | $58 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Chirag JhaveriAustin$240K
- Sheila BarbarinoAustin$232K
- Aaron RollerAustin$202K
- Philip StoreyAustin$161K
- Farhan IrshadAustin$111K
- Edward WoodAustin$110K
- Ryan YoungAustin$105K
- Steven DellAustin$94K
- Shelley GhafooriAustin$73K
- Michael SingerSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.